Literature DB >> 28679847

Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.

Alexander E Merkler1, Setareh Salehi Omran2, Gino Gialdini2, Michael P Lerario2, Shadi Yaghi2, Mitchell S V Elkind2, Babak B Navi2.   

Abstract

BACKGROUND AND
PURPOSE: It is uncertain whether previous ischemic stroke within 3 months of receiving intravenous thrombolysis (tPA [tissue-type plasminogen activator]) for acute ischemic stroke (AIS) is associated with an increased risk of adverse outcomes.
METHODS: Using administrative claims data, we identified adults with AIS who received intravenous tPA at California, New York, and Florida hospitals from 2005 to 2013. Our primary outcome was intracerebral hemorrhage, and our secondary outcomes were unfavorable discharge disposition and inpatient mortality. We used logistic regression to compare rates of outcomes in patients with and without previous ischemic stroke within 3 months of intravenous tPA for AIS.
RESULTS: We identified 36 599 AIS patients treated with intravenous tPA, of whom 568 (1.6%) had a previous ischemic stroke in the past 3 months. Of all patients who received intravenous tPA, the rate of intracerebral hemorrhage was 4.9% (95% confidence interval [CI], 4.7%-5.1%), and death occurred in 10.7% (95% CI, 10.4%-11.0%). After adjusting for demographics, vascular risk factors, and the Elixhauser Comorbidity Index, previous ischemic stroke within 3 months of thrombolysis for AIS was not associated with an increased risk of intracerebral hemorrhage (odds ratio, 0.9; 95% CI, 0.6-1.4; P=0.62), but was associated with an increased risk of death (odds ratio, 1.5; 95% CI, 1.2-1.9; P=0.001) and unfavorable discharge disposition (odds ratio, 1.3; 95% CI, 1.0-1.7; P=0.04).
CONCLUSIONS: Among patients who receive intravenous tPA for AIS, recent ischemic stroke is not associated with an increased risk of intracerebral hemorrhage but is associated with a higher risk of death and unfavorable discharge disposition.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  comorbidity; odds ratio; risk factors; stroke; thrombolytic therapy

Mesh:

Substances:

Year:  2017        PMID: 28679847      PMCID: PMC5663184          DOI: 10.1161/STROKEAHA.117.018119

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe.

Authors:  Michal Karlinski; Adam Kobayashi; Robert Mikulik; Daniel Sanak; Nils Wahlgren; Anna Czlonkowska
Journal:  Int J Stroke       Date:  2012-02-07       Impact factor: 5.266

2.  Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.

Authors:  Adnan I Qureshi; Saqib A Chaudhry; Biggya L Sapkota; Gustavo J Rodriguez; M Fareed K Suri
Journal:  Arch Phys Med Rehabil       Date:  2012-03-21       Impact factor: 3.966

3.  Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study.

Authors:  H S Jørgensen; H Nakayama; J Reith; H O Raaschou; T S Olsen
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

Review 4.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  Bart M Demaerschalk; Dawn O Kleindorfer; Opeolu M Adeoye; Andrew M Demchuk; Jennifer E Fugate; James C Grotta; Alexander A Khalessi; Elad I Levy; Yuko Y Palesch; Shyam Prabhakaran; Gustavo Saposnik; Jeffrey L Saver; Eric E Smith
Journal:  Stroke       Date:  2015-12-22       Impact factor: 7.914

5.  Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event.

Authors:  Michal Karlinski; Adam Kobayashi; Anna Czlonkowska; Robert Mikulik; Daniel Vaclavik; Miroslav Brozman; Zuzana Gdovinova; Viktor Švigelj; Laszlo Csiba; Klara Fekete; Janika Kõrv; Vida Demarin; Vanja Bašic-Kes; Aleksandras Vilionskis; Dalius Jatuzis; Yakup Krespi; Nikolay Shamalov; Silva Andonova; Niaz Ahmed; Nils Wahlgren
Journal:  Stroke       Date:  2015-10-08       Impact factor: 7.914

6.  Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services.

Authors:  A J Coull; J K Lovett; P M Rothwell
Journal:  BMJ       Date:  2004-01-26
  6 in total
  5 in total

1.  Exploring Contraindications for Thrombolysis: Risk of Hemorrhagic Transformation and Neurological Deterioration after Thrombolysis in Mice with Recent Ischemic Stroke and Hyperglycemia.

Authors:  Sarah Gelhard; Roxane-Isabelle Kestner; Moritz Armbrust; Helmuth Steinmetz; Christian Foerch; Ferdinand O Bohmann
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

2.  Effect of atrial fibrillation on endovascular thrombectomy for acute ischemic stroke. A meta-analysis of individual patient data from six randomised trials: Results from the HERMES collaboration.

Authors:  J A Smaal; I R de Ridder; A Heshmatollah; W H van Zwam; Dwj Dippel; C B Majoie; S Brown; M Goyal; Bcv Campbell; K W Muir; A M Demchuck; A Davalos; T G Jovin; P J Mitchell; P White; J L Saver; M D Hill; Y B Roos; A van der Lugt; R J van Oostenbrugge
Journal:  Eur Stroke J       Date:  2020-05-13

3.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.

Authors:  Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc
Journal:  Eur Stroke J       Date:  2021-02-19

4.  The Risk of Symptomatic Intracranial Hemorrhage after Thrombolysis for Acute Stroke: Current Concepts and Perspectives.

Authors:  Pedro J Modrego
Journal:  Ann Indian Acad Neurol       Date:  2019 Jul-Sep       Impact factor: 1.383

5.  Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke.

Authors:  Anil Gulati; Nilesh Agrawal; Deepti Vibha; U K Misra; Birinder Paul; Dinesh Jain; Jeyaraj Pandian; Rupam Borgohain
Journal:  CNS Drugs       Date:  2021-01-11       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.